Daiichi Sankyo Clinical Trial Pipeline — 46 Active Studies

Daiichi Sankyo pipeline at a glance (March 2026)

About the Daiichi Sankyo clinical program

Daiichi Sankyo has emerged as the global leader in antibody-drug conjugate (ADC) oncology through its proprietary DXd payload technology platform. Their collaboration with AstraZeneca on three blockbuster ADCs — Enhertu (trastuzumab deruxtecan, HER2), Dato-DXd (datopotamab deruxtecan, TROP2), and patritumab deruxtecan (HER3) — has reshaped the competitive landscape in breast cancer, NSCLC, and gastric cancer. Enhertu's DESTINY-Breast and DESTINY-Gastric trials have set new benchmarks for HER2-low breast cancer and HER2-positive gastric cancer, expanding the HER2 targetable population. Daiichi Sankyo's wholly-owned pipeline includes ifinatamab deruxtecan (IFD, targeting B7-H3) for small cell lung cancer and other solid tumors, raludotatug deruxtecan (R-DXd, targeting CDH6) for ovarian and kidney cancers, and multiple DXd ADC combinations across indications.

Key therapeutic areas

• Breast cancer (HER2, HER2-low, TROP2, HER3)
• Non-small cell lung cancer (HER2, HER3, TROP2)
• Gastric / gastroesophageal cancer (HER2)
• Small cell lung cancer (B7-H3)
• Ovarian / renal cancer (CDH6)

Key pipeline programs

• Enhertu (trastuzumab deruxtecan) — HER2-targeting DXd ADC
• Dato-DXd (datopotamab deruxtecan) — TROP2 DXd ADC
• Patritumab deruxtecan (HER3-DXd) — HER3 DXd ADC
• Ifinatamab deruxtecan (I-DXd) — B7-H3 DXd ADC, SCLC
• Raludotatug deruxtecan (R-DXd) — CDH6 DXd ADC, ovarian/renal
• DS-6000 — CDH6-targeting DXd ADC

Top Daiichi Sankyo trial indications

Condition / Indication	Trials
["Non-small Cell Lung Cancer"]	3
["Recurrent or Metastatic Solid Tumors"]	2
["Advanced Solid Tumor"]	2
["Metastatic Non Small Cell Lung Cancer"]	2
["Breast Cancer"]	2
["Healthy Subjects"]	2
["Advanced Cancer", "Metastatic Cancer", "Germ Cell Tumor"]	1
["Solid Tumor", "Advanced Cancer", "Metastatic Solid Tumor"]	1

Why monitor Daiichi Sankyo's clinical trial activity

Daiichi Sankyo registers ADC expansion trials across multiple tumor types continuously — every new Enhertu, Dato-DXd, or patritumab deruxtecan trial represents competitive intelligence for companies in breast cancer, NSCLC, and gastric cancer. Their pipeline of next-generation DXd ADCs (IFD for SCLC, R-DXd for ovarian) is closely watched for B7-H3 and CDH6 targeting precedent.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Daiichi Sankyo's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Daiichi Sankyo trials

• Sponsor normalization: Daiichi Sankyo may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What ADC programs is Daiichi Sankyo actively trialing?

Daiichi Sankyo's DXd ADC platform includes: Enhertu (HER2, active in breast/gastric/NSCLC/other HER2-expressing tumors), Dato-DXd (TROP2, breast cancer and NSCLC), patritumab deruxtecan (HER3, NSCLC and breast), ifinatamab deruxtecan (B7-H3, SCLC), and raludotatug deruxtecan (CDH6, ovarian/renal). Each program generates multiple combination and expansion trials.

How many Daiichi Sankyo trials are currently recruiting?

Based on current ClinicalTrials.gov data, 26 Daiichi Sankyo-sponsored trials are actively recruiting patients globally. Note that Enhertu and Dato-DXd trials listed under AstraZeneca as lead sponsor are additionally covered on the AstraZeneca pipeline page.

How does DataLookout handle the AstraZeneca/Daiichi Sankyo collaboration trials?

Trials may be registered under AstraZeneca or Daiichi Sankyo as the lead sponsor depending on the development arrangement. DataLookout's sponsor normalization ensures Daiichi Sankyo-registered trials are captured on this page, while AstraZeneca-registered collaboration trials appear on the AstraZeneca page. Monitor both sponsors for complete Enhertu and Dato-DXd pipeline coverage.